Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older, of any gender.
- People who have been diagnosed with lung cancer confirmed through laboratory testing of a tissue or cell sample.
- People who have had a specific type of advanced genetic testing (called next-generation sequencing) done on their tumour sample at an approved laboratory.
- People who have at least one tumour or lesion that can be measured using standard imaging guidelines.
- People who are expected to live for at least 3 months or more.
- People whose overall health and ability to carry out daily activities meets a certain standard, as assessed by their doctor using a recognised scale (confirm with trial site).
- People who have read, understood, and signed a consent form agreeing to take part in the study.
- People who are willing and able to attend scheduled visits and follow the study procedures.
- For one specific group in the trial (Cohort A): people whose lung cancer has a confirmed EGFR mutation, which is a specific change in the cancer's genetic makeup.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have an implanted electronic device, such as a pacemaker, in the upper chest or torso area.
- People who have been diagnosed with another type of cancer in the past 3 years (though some exceptions may apply for certain treated skin cancers, cervical cancer in situ, or prostate cancer — confirm with trial site).
- People who have any other health condition or illness that the trial doctor believes could affect their safety or interfere with the study results.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +972587040620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Molecular ctDNA characterization under concomitant TTFields therapy - cohort A (EGFR); In vitro peripheral lymphocytes activity characterization under concomitant TTFields therapy - cohort B (under PD-1 inhibitors treatment); Characterization of the impact of TTFields on peripheral lymphocytes proliferation ex-vivo - cohort B (PD-1 inhibitors treatment)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.